salicylates and rhyncophylline

The EphA4 receptor has been proposed to be a key actor in neurodegenerative diseases. In the last years, several research groups focused their efforts on the discovery of small molecules capable of blocking EphA4 activity by binding its extracellular domain. However, none of the compounds so far identified possess adequate chemical and/or pharmacological profiles to assess the "druggability" of EphA4 in animal models. New efforts are required to deliver a new generation of suitable pharmacological tools.

Topics: Animals; Humans; Indole Alkaloids; Models, Molecular; Neurodegenerative Diseases; Oxindoles; Pyrroles; Receptor, EphA4; Salicylates; Signal Transduction